File
Authors
Kubouchi, Yasuaki Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine
Kidokoro, Yoshiteru Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine Researchers DB
Ohno, Takashi Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine
Yurugi, Yohei Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine
Wakahara, Makoto Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine Researchers DB
Haruki, Tomohiro Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine Researchers DB KAKEN
Nakamura, Hiroshige Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine Researchers DB KAKEN
Keywords
epidermal growth factor receptor tyrosine kinase inhibitors
non-small cell lung cancer
post recurrecurrence
prognostic factor
Abstract
[Background]Recurrence of lung cancer after surgical resection is a major obstacle in the cure and long-term survival of patients and has become the most common cause of death. However, prognostic factors and efficacy of therapy after recurrence remain controversial. We evaluated the prognostic factors of post recurrence survival (PRS) in patients of resected stage I non-small cell lung cancer (NSCLC).
[Methods]Of the 551 patients who underwent surgery for stage I NSCLC between 2005 and 2013, we reviewed 89 (16.2%) patients who had recurrence. We examined PRS using the Kaplan–Meier method and multivariate Cox regression analyses.
[Results]The median follow-up period after recurrence was 21.0 months. The median recurrence free interval (RFI) was 16.8 months. The 1-year PRS and 3-year PRS were 65.6% and 44.7%, respectively. Multivariate analysis revealed that size of primary lesion > 25 mm (P = 0.048), RFI ≤ 17 months (P = 0.048) and no treatment for recurrence (P < 0.001) were independent poor-prognosis factors of PRS. We further examined PRS in 66 patients who underwent any post recurrence therapy. For the patients who underwent treatment after recurrence, bone metastasis (P = 0.025) and treatment without epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) (P = 0.049) were independent poor prognostic factors.
[Conclusion]PRS may be associated with characteristics of a recurrent lesion, including the biology of the recurrent tumor, RFI, recurrent site, the treatment for recurrence, rather than characteristics of primary lesion. Although further validation is needed, this information is important for the design of clinical trials for post-recurrence therapy.
Publisher
Tottori University Faculty of Medicine
Content Type
Journal Article
ISSN・ISBN
1346-8049
NCID
AA00892882
Journal Title
Yonago Acta Medica
Current Journal Title
Yonago Acta Medica
Volume
60
Issue
4
Start Page
213
End Page
219
Published Date
2018-02-05
Text Version
Publisher
Citation
Yonago Acta Medica. 2017,60(4),213–219
Department
Faculty of Medicine/Graduate School of Medical Sciences/University Hospital
Language
English